CIMR-Qing Deng

Research Group

Qing Deng

qdeng(at)cimrbj.ac.cn

Assistant Investigator

qdeng(at)cimrbj.ac.cn

B.S. in Biotechnology, Soochow University, China

Ph.D. in Biochemistry & Molecular Biology, Shanghai Jiao Tong University School of Medicine, China

Work Experience

2025-Present

Assistant Investigator, Chinese Institutes for Medical Research, Beijing, China

2017-2024

Research Scientist/Instructor, The University of Texas MD Anderson Cancer Center, Texas, USA

2014-2017

Postdoctoral Associate, Baylor College of Medicine, Texas, USA

2009-2014

Postdoctoral Fellow/Research Associate, Chinese National Human Genome Center at Shanghai, Shanghai, China

Research Direction

The Deng laboratory at CIMR is committed to elucidating the role of B cell heterogeneity in tumor development, metastasis and responses to immunotherapy. Our objective is to achieve a deeper understanding of the pathological mechanism associated B cells and tertiary lymphoid structures in prevalent solid tumors, as well as develop potential therapeutic strategies aimed at reprogramming B cell fate.

Major Research Projects

1. Explore molecular mechanisms regulating the germinal center-dependent/independent responses of tumor-infiltrating B cells.

2. Uncover mechanisms of B cell maturation and selection in tertiary lymphoid structures.

3. Identify molecular targets and signaling pathways that can reprogram B cell fate in non-lymphoid tissues.

Major Contributions

1. Identified mutated genes of SWI/SNF chromatin remodeling complex and its molecular mechanisms regulating on malignant characteristics and fate determination of tumor cells (Cancer Cell, 2024; Nature Genetics, 2012).

2. Revealed cellular and molecular features that associated with efficacy and toxicity of CD19 CAR-T cell therapy in relapsed or refractory large B-cell lymphoma (Nature Medicine, 2020; Cell Reports Medicine, 2023; Cancer Cell, 2023; Blood Advances, 2023).

3. Characterized the tumor microenvironment across different subtypes of B-cell lymphoma, with a specific focus on identifying biological features associated with tumor cell mutations, and antigen presentation mechanisms (Blood Cancer Discovery, 2022), as well as response to CD19 CAR-T cell therapy (Cancer Cell, Under Review).

Representative Publications *：Co-first author; #：Co-corresponding author

Deng Q*, Lakra P*, Gou P*, Yang H, Meydan C, Teater M, Chin CR, Li X, Rojas-Neira E, Liu W, Reville P, Kizhakeyli A, Parsons S, Wilson A, Herderson J, Scull B, Gurumurthy G, Vega F, Chadburn A, Cuglievan B, El-Mallawany N, Allen C, Mason CE, Melnick A, Green MR. Smarca4 is a haploinsufficient B-cell tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell, 2024, 42: 605-622.e11. DOI: 10.1016/j.ccell.2024.02.011

Strati P*, Li X*, Deng Q*, Marques-Piubelli M, Henderson J, Balada G, Deaton L, Cain T, Yang H, Ravanmehr V, Fayad L, Iyer S, Nastoupil L, Hagemeister F, Fowler N, Westin J, Steiner R, Nair R, Flowers C, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu S#, Green MR#. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Reports Medicine, 2023, 4: 101158. DOI: 10.1016/j.xcrm.2023.101158

Han G*, Deng Q*, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L#, Green MR#. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discovery, 2022,3: 428-443. DOI: 10.1158/2643-3230.BCD-21-0075

Li X, Henderson J, Gordon M, Sheikh I, Nastoupil L, Westin J, Flowers C, Ahmed S, Wang L, Neelapu S, Strati P, Deng Q#, Green MR#. A single-cell atlas of CD19 chimeric antigen receptor T cells. Cancer Cell, 2023, 41: 1835-1837. DOI: 10.1016/j.ccell.2023.08.015

Deng Q*, Han G*, Puebla-Osorio N, Ma M, Strati P, Chasen B, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Dai E, Hagemeister F, Fayad L, Saminiego F, Lee H, Nastoupil L, Fowler N, Davis R, Westin J, Neelapu S#, Wang L#, Green MR#. Characteristics of anti-CD19 CAR T-cell infusion products associated with efficacy and toxicity in patients with large B-cell lymphomas. Nature Medicine, 2020, 26: 1878-1887. DOI: 10.1038/s41591-020-1061-7

Full List of Publications Can Be Found here